Answers are grounded in this paper and cite their sources.
• Immune checkpoint inhibitors show promise in oral cancer treatment. • Pembrolizumab and nivolumab offer new options for OSCC. • Immunotherapy targets immune checkpoints to fight OSCC. • Combining immunotherapy with other treatments enhances efficacy. • Challenges include managing immune-related adverse events in OSCC therapy.
No takes yet. Share an insight, caveat, or question.
Santosh Patil (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: